Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abelacimab (Primary)
  • Indications Embolism; Stroke; Thrombosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ANT-010; LILAC-TIMI 76
  • Sponsors Anthos Therapeutics

Most Recent Events

  • 13 Jul 2026 Planned End Date changed from 31 Oct 2026 to 30 Dec 2027.
  • 13 Jul 2026 Planned primary completion date changed from 31 Aug 2026 to 30 Dec 2027.
  • 23 Mar 2026 Planned number of patients changed from 1900 to 2228.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top